Trilateral Project 24.1-Biotechnology 202

Yes, the judgment would depend on whether antigen A is novel or not. If it were known, then it would in principal be possible to obtain monoclonal antibodies directed against antigen A without inventive skill. In this case, a claim directed to a group of monoclonal antibodies having different properties would lack unity of invention. If, however, the claimed monoclonal antibodies shared a novel, non-obvious feature, then unity would be recognized. On the other hand, where antigen A is novel and inventive, then a group of monoclonal antibodies directed against antigen A would be unitary.